FIM
EGRX

Freedom Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Freedom Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,282
Closed -$336K – 1236
2017
Q4 		$336K Buy
6,282
+51
+0.8% +$2.84K 0.02% 840
2017
Q3 		$372K Buy
+6,231
New +$377K 0.02% 735

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Freedom Investment Management's EGRX Position: Q1 2018 in Review

Freedom Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2018, closing a stake of 6,282 shares — an estimated $336K sold.

Freedom Investment Management first reported a position in EGRX in Q3 2017 and held it in 2 quarters. The position peaked at $372K in Q3 2017. 174 funds tracked by Wall St. Rank hold EGRX as of Q1 2018.

  • Freedom Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Freedom Investment Management sold 6,282 Eagle Pharmaceuticals, Inc. shares in Q1 2018, an estimated $336K.
  • Freedom Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Freedom Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $372K in Q3 2017.
  • 174 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2018.

Based on Freedom Investment Management's 13F filing for Q1 2018, filed 6 Apr 2018.